Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

Allison Martell & Allison Lampert  |  

TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s…

WHO Drug Pricing Talks May Fail to End Secrecy, Activists Fear

Tom Miles  |  

GENEVA (Reuters)—Governments are working on a drug pricing transparency deal at the World Health Organization’s (WHO) annual assembly, but activists said on Thursday they fear crucial costs may be left out, enabling pharmaceutical firms to keep prices high. Campaigners say some drugs are exhorbitantly priced, even though they are often developed with public funding, and…

Social Conflict Seeps into Medical Societies

Tamara Mathias  |  

In U.S. medical society boardrooms, far from legislative chambers, social conflict is forcing board members to deal with laws that raise issues of medical ethics. Take the Association of University Radiologists (AUR), a group of more than a thousand medical school radiology faculty whose stated mission is to “inspire and educate the academic radiology community.”…

U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug

Andrew Chung  |  

WASHINGTON (Reuters)—On May 20, the U.S. Supreme Court threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug alendronic acid (Fosamax). The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit…

Until Broadband Access Improves, Telemedicine Won’t Help Rural Communities

Linda Carroll  |  

(Reuters Health)—Telemedicine has been touted as a solution to the dearth of doctors in rural America. But the same places where residents must drive many miles to see a physician often also have limited broadband access, a new study suggests. About 25% of Americans live in rural communities while a mere 10% of physicians practice…

ACR Hill Visits Yield Key Bill Support; Plus Medicare, Biosimilar Wins

Angus Worthing, MD, FACP, FACR  |  

Greetings from Washington, D.C., where ACR leaders just held more than 100 meetings on Capitol Hill supporting reforms to step therapy and prior authorization, increased reimbursement for dual-energy X-ray absorptiometry (DXA), solutions to the rheumatology workforce shortage, and rheumatology-specific research at the Pentagon. We’re already hearing great news about our successes: Hours after our visit,…

Recent Trials Investigated Targeted Therapies for Systemic Sclerosis

  |  

SNOWMASS VILLAGE, COLO.—Data from three recent trials in systemic sclerosis (scleroderma) provide information on a number of important issues related to screening and treatment. First presented at the 2018 ACR/ARHP Annual Meeting, the phase 2/3 trials assessed the safety and efficacy of targeted agents to treat patients with systemic sclerosis.1-3 In a follow-up presentation at…